Orthocell Announces Record Revenue of $3m for September Quarter

• Record quarterly revenue of $3.0m (up 9.1% from June quarter) 
• Sixth consecutive quarter of record revenue 
• CQGR of 9.5% since Q2 FY23 launch 
• ~$27.0m cash and no debt 
• US rollout accelerating with >100 surgeons introduced & 11 hospital approvals secured 
• First Canadian distributor appointed – initial sales targeted for December quarter 

“The record revenue result for the September quarter is a particularly pleasing result, given it has largely been achieved from our existing markets in Australia and Singapore.  It’s a tangible confirmation that surgeons are growing increasingly comfortable using Remplir in nerve repair procedures.”